Lutetium[177Lu] Oxodotreotide is named as a drug or biological intervention in 2 clinical trials in our China trial register, 1 of which is recruiting. The lead sponsor is Sinotau Pharmaceutical Group. Registered phases: Phase 3 and Phase 2/3. Conditions studied include Neuroendocrine Tumors; Advanced Neuroendocrine Neoplasm.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT06398444 | A Clinical Study of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Neuroendocrine Neoplasms (ClinicalTrials.gov ↗) Advanced Neuroendocrine Neoplasm |
Phase 2/3 | Recruiting |
| NCT05459844 | A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs (ClinicalTrials.gov ↗) Neuroendocrine Tumors |
Phase 3 | Active, closed |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Neuroendocrine Tumors | 1 |
| Advanced Neuroendocrine Neoplasm | 1 |
| Lead sponsor | Trials |
|---|---|
| Sinotau Pharmaceutical Group | 2 |
| Register | Lutetium[177Lu] Oxodotreotide trials |
|---|---|
| Clinical trials in China | 2 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Lutetium[177Lu] Oxodotreotide works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Lutetium[177Lu] Oxodotreotide (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.